Leukemija klinikiniai tyrimai Misūris
6 tyrimai dėl Leukemija ieško dalyvių vietose Misūris.
Miestai Misūris
Oficialus tyrimo tekstas (anglų kalba)
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Washington University in St. Louis School of Medicine, St Louis
Renkami dalyviai1/2 fazė
30 Days · Visoms lytims · Atnaujinta 2026-09-16 · NCT04065399Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Washington University School of Medicine, St Louis
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-20 · NCT06001788Integrated Cancer Repository for Cancer Research
- Saint Luke's Cancer Institute, East, Kansas City
- Saint Luke's Cancer Institute, Kansas City
- Saint Luke's Cancer Institute, Kansas City North, Kansas City
- ir dar 3
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 19 iki 110 · Visoms lytims · Atnaujinta 2026-06-29 · NCT02012699Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Washington University School of Medicine, St Louis
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-05-18 · NCT01790152SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Kansas City
- Massive Bio SYNERGY-AI site, St Louis
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2025-10-28 · NCT03452774A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Kansas City VA Medical Center, Kansas City, MO, Kansas City
Renkami dalyviai2 fazė
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2025-10-14 · NCT06520098Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.